In this study, we report that a mitogen-activated protein kinase (MAPK)/p38 isoform, MAPK13/p38δ, is a downstream target of the mTORC1–m6A RNA modification pathway, which likely contributes to the limited tumor-suppressive effects of rapamycin. The gene discussed is MAPK14; the disease is neoplasm.